Cybin (OTCMKTS:CYBN) Stock Price Down 2%

Cybin Inc. (OTCMKTS:CYBN)’s share price was down 2% on Thursday . The company traded as low as $0.36 and last traded at $0.37. Approximately 1,714,145 shares changed hands during trading, a decline of 67% from the average daily volume of 5,246,800 shares. The stock had previously closed at $0.38.

Cybin Stock Down 2.0 %

The business has a 50-day moving average price of $0.39 and a two-hundred day moving average price of $0.43. The firm has a market cap of $151.19 million, a PE ratio of -1.75 and a beta of 0.43.

Cybin (OTCMKTS:CYBN) last posted its quarterly earnings data on Wednesday, February 14th. The company reported ($0.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.04). On average, equities research analysts predict that Cybin Inc. will post -0.19 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Cybin

Several large investors have recently bought and sold shares of the business. Moneta Group Investment Advisors LLC increased its holdings in Cybin by 133,816.7% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 66,405,251 shares of the company’s stock valued at $19,729,000 after buying an additional 66,355,664 shares during the last quarter. Penserra Capital Management LLC increased its holdings in Cybin by 55.8% in the first quarter. Penserra Capital Management LLC now owns 407,309 shares of the company’s stock valued at $223,000 after buying an additional 145,929 shares during the last quarter. Belpointe Asset Management LLC grew its holdings in shares of Cybin by 21.5% during the first quarter. Belpointe Asset Management LLC now owns 313,705 shares of the company’s stock worth $121,000 after purchasing an additional 55,600 shares during the last quarter. Royal Bank of Canada grew its holdings in shares of Cybin by 926.4% during the third quarter. Royal Bank of Canada now owns 109,239 shares of the company’s stock worth $52,000 after purchasing an additional 98,596 shares during the last quarter. Finally, Virtu Financial LLC grew its holdings in shares of Cybin by 104.0% during the fourth quarter. Virtu Financial LLC now owns 90,467 shares of the company’s stock worth $27,000 after purchasing an additional 46,129 shares during the last quarter. Hedge funds and other institutional investors own 17.94% of the company’s stock.

About Cybin

Cybin Inc, a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation.